 BrainsWay Ltd. NASDAQ TASE: BWAY BrainsWay or the Company, a global leader in the advanced non-invasive treatment of brain disorders, today announced a preliminary, unaudited revenue range for the first quarter ended March 31, 2020. Specifically, the Company expects first quarter revenues to be within the range of 3.9 million to 4.2 million. Our revenue estimate for the first quarter reflects the impact that the COVID-19 global health pandemic is having on our business, said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. 